Perspective Therapeutics, Inc. (CATX) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CATX Revenue Growth
CATX Revenue Analysis (2013–2024)
As of May 8, 2026, Perspective Therapeutics, Inc. (CATX) generated trailing twelve-month (TTM) revenue of $576,000. The most recent quarter (Q2 2025) recorded $234,000 in revenue, down 31.6% sequentially.
Looking at the longer-term picture, CATX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.8 million in 2021.
When compared to Healthcare sector peers including AGEN (+10.4% YoY), RNW (+50.5% YoY), and LNTH (+0.6% YoY). Compare CATX vs AGEN →
CATX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CATXCurrent | $576,000 | - | - | - | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 RNW | $97.1B | +50.5% | +14.9% | 53.5% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 NVX | $6M | +24.0% | +6.6% | -880.0% |
CATX Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | -100.0% | $0 | - | $10.5M | - |
| 2023 | $1.4M | -79.8% | $1.4M | 100.0% | $-40,941,000 | -2855.0% |
| 2022 | $7.1M | -34.2% | $1.6M | 23.0% | $-15,182,000 | -213.7% |
| 2021 | $10.8M | +7.4% | $4.6M | 42.8% | $-7,391,000 | -68.5% |
| 2020 | $10.1M | +3.9% | $5.1M | 50.9% | $-3,437,000 | -34.2% |
| 2019 | $9.7M | +32.3% | $5.1M | 52.9% | $-3,476,000 | -35.9% |
| 2018 | $7.3M | +23.5% | $3.0M | 41.7% | $-5,278,000 | -72.2% |
| 2017 | $5.9M | +24.4% | $1.8M | 31.1% | $-6,729,000 | -113.6% |
| 2016 | $4.8M | -0.2% | $838K | 17.6% | $-6,307,000 | -132.5% |
| 2015 | $4.8M | +3.5% | $129K | 2.7% | $-5,082,003 | -106.6% |
See CATX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CATX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CATX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCATX — Frequently Asked Questions
Quick answers to the most common questions about buying CATX stock.
Is CATX's revenue growth accelerating or slowing?
CATX TTM revenue: $576000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CATX's long-term revenue growth rate?
Perspective Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CATX's revenue distributed by segment?
CATX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.